| Date Filed | Type | Description |
| 04/07/2021 |
GN
| BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference |
| 03/19/2021 |
GN
| BioCryst Appoints Helen Thackray, M.D., as Chief Research and Development Officer |
| 02/25/2021 |
GN
| BioCryst Receives Positive CHMP Opinion for ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema |
| 02/09/2021 |
GN
| BioCryst to Present Data at 2021 American Academy of Allergy, Asthma & Immunology Annual Meeting |
| 02/03/2021 |
GN
| BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB® Expanding Patient Population to Include Children Six Months and Older |
| 01/22/2021 |
GN
| BioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema |
| 01/07/2021 |
GN
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 01/06/2021 |
GN
| BioCryst to Present at 39th Annual J.P. Morgan Healthcare Conference |
| 12/22/2020 |
GN
| BioCryst Provides Update on Galidesivir Program |
| 12/21/2020 |
GN
| BioCryst Announces Positive Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans Progressiva |
| 12/16/2020 |
GN
| BioCryst Announces U.S. Availability of ORLADEYO™ (berotralstat) for the Treatment of Hereditary Angioedema |
| 12/11/2020 |
GN
| BioCryst to Present at JMP Securities Hematology Summit |
| 12/07/2020 |
GN
| Royalty Pharma Acquires Royalty Interest in ORLADEYO and BCX9930 From BioCryst Pharmaceuticals |
| 12/07/2020 |
GN
| BioCryst Announces $325 Million of Funding from Royalty Pharma and Athyrium Capital Management |
| 12/06/2020 |
GN
| BioCryst's Oral Factor D Inhibitor (BCX9930) Shows High Potency and Specificity for Alternative Pathway of Complement |
| 12/03/2020 |
GN
| BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients |
| 12/01/2020 |
GN
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 11/20/2020 |
GN
| BioCryst to Present at Upcoming Virtual Investment Conferences |
| 11/13/2020 |
GN
| BioCryst Presents Data Showing Sustained Attack Rate Reductions, Improved Patient Satisfaction and Quality of Life for HAE Patients Taking Berotralstat in APeX-2 Trial |
| 11/12/2020 |
GN
| BioCryst to Present Data at the 2020 ASH Annual Meeting |
| 11/02/2020 |
GN
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 10/30/2020 |
GN
| MHRA Grants HAE Patients Early Access to BioCryst's Berotralstat in United Kingdom |
| 10/22/2020 |
GN
| BioCryst to Report Third Quarter 2020 Financial Results on November 5 |
| 10/05/2020 |
GN
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 09/30/2020 |
GN
| BioCryst's Oral Factor D Inhibitor, BCX9930, Shows Clinical Benefit as Monotherapy Through 400 mg bid in Treatment-naïve PNH Patients |
| 09/03/2020 |
GN
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 08/31/2020 |
GN
| NIAID Awards BioCryst New $44 Million Contract to Advance Development of Galidesivir |
| 08/31/2020 |
GN
| FDA Grants Orphan Drug Designation for BCX9930 in PNH |
| 08/06/2020 |
GN
| BioCryst Reports Second Quarter 2020 Financial Results and Upcoming Key Milestones |
| 08/04/2020 |
GN
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 07/23/2020 |
GN
| BioCryst to Report Second Quarter 2020 Financial Results on August 6 |
| 07/02/2020 |
GN
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |